Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2023-12-29 00:00:00 ET · period of report 2023-12-29 · accession 0000950170-23-073904 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2023-12-29 | 2023-12-29 | SYRE | Fairmount Healthcare Fund II L.P. | Dir, 10% | J - Other | $0.00 | -2.62M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-29 | J | A | 406,038 | $0.00 | 406,038 | I By Tomas Kiselak | — | — | |
| 2 | Common | Common Stock | 2023-12-29 | J | A | 406,038 | $0.00 | 406,038 | I By Peter Harwin | — | — | |
| 3 | Common | Common Stock | 2023-12-29 | J | D | 3,435,480 | $0.00 | 0 | I By Fairmount Healthcare Co-Invest L.P. | — | — | (F2) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |